

ACTIVE CONCEPTS LLC

107 Technology Drive, Lincolnton | NC 28092 USA • <u>info@activeconceptsllc.com</u> • Phone: +1-704-276-7100 • Fax: +1-704-276-7101 • <u>https://activeconceptsllc.com/</u>

Tradename: AC PomeaShield

<u>Code:</u> 16935

CAS #: 7732-18-5 & 84961-57-9 & 1686112-36-6 (or) 68333-16-4

Test Request Form #: 9263

Lot #: N220316M

Sponsor: Active Concepts, LLC; 107 Technology Drive Lincolnton, NC 28092 Study Director: Maureen Drumwright Principle Investigator: Daniel Shill

Test Performed:

Senescence-Associated β -galactosidase (SA- β -gal) Activity Cellular Aging Model: Fibroblasts

Introduction

Cellular senescence is a state of permanent cell cycle arrest that accompanies aging and contributes to a decline in normal skin function and physiology. Senescence is characterized by changes in cellular morphology, metabolism, signaling pathways, and biochemical profiles that manifest as increased collagen breakdown, wrinkles, and thin skin. SA- β -gal is the gold standard biomarker to identify senescence in vitro as the enzyme β -galactosidase explicitly accumulates in the lysosomes of senescent cells.

Accordingly, a cellular aging model was developed to assess the *in vitro* effect of **AC PomeaShield** to reduce SA- β -gal activity in "aged" fibroblasts. Attenuating cellular senescence could blunt or prevent the age-related decline in skin function and physiology.

Assay Principle

A model of cellular aging was developed by utilizing fibroblasts at different passage numbers (P), which represent the number of times cells have been harvested and reseeded into subsequent cell culture vessels (i.e. the higher the passage number, the more times those cells have been harvested and reseeded). Fibroblasts at low passages (\leq P5) demonstrate morphological, metabolic, and senescent biomarker profiles matching that of young skin *in vivo*. Conversely, fibroblasts at high passages (\geq P8) exhibit the cellular characteristics of older skin *in vivo*.

Hoechst and SPiDER- β Gal dyes were utilized in conjunction to provide a specific and quantitative method for determining cellular senescence. Hoechst, a cell-permeant dye, fluoresces brightly when bound to nuclear DNA to indicate cellular nuclei, whereas SPiDER- β Gal fluoresces when bound to β -galactosidase indicating cellular senescence. SA- β -gal activity is normalized by displaying the relative fluorescent units (RFU) from the SPiDER- β Gal dye (β -galactosidase Signal) as a function of the Hoechst dye (Nuclear Signal) RFU and set relative to "young" fibroblasts to underscore the effect of cellular aging on senescence.

Information contained in this technical literature is believed to be accurate and is offered in good faith for the benefit of the customer. The company, however, cannot assume any liability or risk involved in the use of its chemical products since the conditions of use are beyond our control. Statements concerning the possible use of our products are not intended as recommendations to use our products in the infringement of any patent. We make no warranty of any kind, expressed or implied, other than that the material conforms to the applicable standard specification.



ACTIVE CONCEPTS LLC

107 Technology Drive, Lincolnton | NC 28092 USA • info@activeconceptsllc.com • Phone: +1-704-276-7100 • Fax: +1-704-276-7101 • https://activeconceptsllc.com/

Materials

A. Kit:	Cellular Senescence Plate Assay Kit – SPiDER-ßGal (Dojindo, SG05)*
B. Incubation Conditions:	37°C, 5% CO ₂ , and 95% relative humidity (RH)
C. Equipment:	Forma humidified incubator, ESCO biosafety laminar flow hood, Synergy HT Microplate
	reader; Pipettes; Light microscope
D. Cell Line:	Normal Human Dermal Fibroblasts (ATCC; PCS-201-012)*
E. Media/Buffers:	Fibroblast Basal Medium (PCS-201-030)*; Fibroblast Growth Kit (PCS-201-041)*;
	Phosphate Buffered Saline (PBS)
F. Reagents:	Hoechst 33342 (ThermoFisher Scientific, 62249)*; Dimethyl Sulfoxide (DMSO)
G. Culture Plate:	96 Well Black Side/Clear Bottom Tissue Culture Treated Microplates
H. Other:	Sterile disposable pipette tips
*Or suitable alternatives su	ibject to change without notice based off vendor availability

suitable alternatives, subject to change without notice based on vehicle availability

Methods

"Young" and "aged" human dermal fibroblasts from the same lot were seeded into a 96-well tissue culture microplate and grown to 80%-90% confluency in complete media (CM) at 37°C. "Young" fibroblasts were utilized in this assay at passage P4, while "aged" fibroblasts were utilized at passage P8. "Young" and "aged" fibroblasts incubated with CM only are utilized as controls, whereas 0.01%, 0.1% and 1.0% concentrations of AC PomeaShield in CM were added to "aged" fibroblasts only. Following a 24-hour incubation, the media in all wells was removed and cells were washed once with PBS. The nuclear dye Hoechst was diluted in CM, added to all wells at final concentration of 10 µM, and incubated at 37°C.

Following a 30-minute incubation, the Hoechst dye was removed, all cells were washed once with PBS, CM was added to all wells, and fluorescence measurements were taken to determine the Nuclear Signal (excitation: 361 nm / emission: 486 nm). Subsequently, the CM was removed, all cells were washed once with PBS, and Lysis Buffer was added to each well. After a 10-minute incubation at room temperature, the SPiDER-ßGal dye was added to each well and incubated for 30 minutes at 37°C. The Stop Solution was then added to each well and fluorescence measurements were taken to determine the β -galactosidase Signal (excitation: 535 nm / emission: 580 nm).

To account for differences in cell counts, normalized SA- β -gal activity is calculated as the β -galactosidase Signal (SPiDERßGal dye) divided by the Nuclear Signal (Hoechst dye), as shown by the following equation:

Normalized SA-
$$\beta$$
-gal Activity = $\frac{\beta$ -galactosidase Signal Nuclear Signal

SA-β-gal activity is displayed as relative to the normalized SA-β-gal activity in "young" fibroblasts by the following equation:

$$SA-\beta-gal\ Activity = \frac{Normalized\ SA-\beta-gal\ Activity_{Sample}}{Normalized\ SA-\beta-gal\ Activity_{Young\ Fibroblasts}}$$

Percent change is calculated from the SA-β-gal activity in "aged" fibroblasts and calculated by the following equation:

 $Percent Change (\%) = \frac{SA - \beta - gal Activity_{Sample} - SA - \beta - gal Activity_{Aged Fibroblasts}}{SA - \beta - gal Activity_{Aged Fibroblasts}} \times 100$

Information contained in this technical literature is believed to be accurate and is offered in good faith for the benefit of the customer. The company, however, cannot assume any liability or risk involved in the use of its chemical products since the conditions of use are beyond our control. Statements concerning the possible use of our products are not intended as recommendations to use our products in the infringement of any patent. We make no warranty of any kind, expressed or implied, other than that the material conforms to the applicable standard specification



ACTIVE CONCEPTS LLC

107 Technology Drive, Lincolnton | NC 28092 USA • info@activeconceptsllc.com • Phone: +1-704-276-7100 • Fax: +1-704-276-7101 • https://activeconceptsllc.com/

Results

The data obtained from this study met criteria for a valid assay and the controls performed as anticipated. Compared to "aged" fibroblasts, "young" fibroblasts demonstrated lower levels of SA- β -gal activity. "Aged" fibroblasts treated with AC **PomeaShield** at 0.01%, 0.1%, and 1.0% exhibited a reduction in SA-β-gal activity compared to untreated "aged" fibroblasts.



Figure 1. The effect of AC PomeaShield on cellular senescence levels in "aged" fibroblasts.



Improvements in Cellular Senescence Levels

Figure 2. The reduction of cellular senescence levels in AC PomeaShield-treated "aged" fibroblasts.

Information contained in this technical literature is believed to be accurate and is offered in good faith for the benefit of the customer. The company, however, cannot assume any liability or risk involved in the use of its chemical products since the conditions of use are beyond our control. Statements concerning the possible use of our products are not intended as recommendations to use our products in the infringement of any patent. We make no warranty of any kind, expressed or implied, other than that the material conforms to the applicable standard specification



ACTIVE CONCEPTS LLC

107 Technology Drive, Lincolnton | NC 28092 USA • <u>info@activeconceptsllc.com</u> • Phone: +1-704-276-7100 • Fax: +1-704-276-7101 • <u>https://activeconceptsllc.com/</u>

Discussion

As shown in Figure 1, "aged" fibroblasts demonstrated 142% higher levels of SA-β-gal activity compared to "young" fibroblasts. These data demonstrate "young" fibroblasts exhibit reduced levels of cellular senescence compared to "aged" fibroblasts.

However, "aged" fibroblasts treated with **AC PomeaShield** at 0.01%, 0.1%, and 1.0% elicited 22%, 27%, and 34% reductions in SA- β -gal activity compared to untreated "aged" fibroblasts, respectively (Figure 2). These data demonstrate **AC PomeaShield** attenuates cellular senescence in "aged" fibroblasts.

Senescence is a hallmark characteristic of cellular aging that contributes to the age-associated modifications of skin function and composition in vivo, such as increased dermal thinning, loss of elasticity, and the development of wrinkles. Specifically, cellular senescence is associated with increased inflammation, oxidative stress, and impaired collagen homeostasis. Collectively, these data indicate that **AC PomeaShield** reduces cellular senescence and may attenuate or reverse the alterations in skin structure and physiology that occur during aging.

Information contained in this technical literature is believed to be accurate and is offered in good faith for the benefit of the customer. The company, however, cannot assume any liability or risk involved in the use of its chemical products since the conditions of use are beyond our control. Statements concerning the possible use of our products are not intended as recommendations to use our products in the infringement of any patent. We make no warranty of any kind, expressed or implied, other than that the material conforms to the applicable standard specification.